Cytotoxic activity and the effect of trisindoline 1 against the cell cycle of breast cancer T47D cell line

Breast cancer is the most common cancer suffered by women in the world, but current chemotherapy treatment has normal cell killing side effect in patients. One of the compounds used as a new anticancer is Trisindoline. This study was conducted to test the cytotoxicity of Trisindoline 1 or 5'-nitro [3,3': 3', 3"-terindoline]-2’one against T47D breast cancer cells and to determine its inhibitory activity against the cell cycle of T47D cell line. The method used was Micro tetrazolium (MTT) assay to obtain inhibitory concentration 50 (IC₅₀) values. Doxorubicin was used as positive control. The cell cycle analysis of the T47D was obtained by flow cytometry method using concentrations of ½ IC₅₀, the IC₅₀, and 2 IC₅₀. The IC₅₀ value of Trisindoline 1 against T47D cell line was 6.145 µg/ml; higher than Doxorubicin’s IC₅₀ value which was 0.145 µg/ml. Cell cycle-assay after the addition of Trisindoline 1 indicated cell cycle arrest during G0-G1-phase and also increased cell accumulation in sub-G1 which showed the apoptotic cells. The cytotoxic mechanism of Trisindoline 1 was due to the oxidation process of indole into indirubin that inhibited Cyclin Dependent Kinases (CDKs) activities.